3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
6
Fallopian Tube Neoplasms
4
Carcinoma, Ovarian Epithelial
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Platinum-resistant Ovarian Cancer
1
Ovarian Cancer Recurrent
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Adenoviridae Infections
1
Interventions
Rituximab
52
Cyclophosphamide
49
Lenalidomide
40
fludarabine
24
obinutuzumab
22
Prednisone
18
Magnetic Resonance Spectroscopy
18
Bendamustine Hydrochloride
18
Vincristine
16
fludarabine phosphate
15
Specimen Handling
15
Doxorubicin
15
zanubrutinib
13
Biopsy
12
tazemetostat
10
ibrutinib
10
Whole-Body Irradiation
10
pembrolizumab
9
Peripheral Blood Stem Cell Transplantation
9
venetoclax
8
Mycophenolic Acid
7
Etoposide
7
axicabtagene ciloleucel
6
Radiotherapy
6
CT-P10
6
Therapeutics
5
R-CHOP protocol
5
tisagenlecleucel
4
tafasitamab
4
polatuzumab vedotin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
1-dodecylpyridoxal
×
1 year
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled